Clinical Utility of Nuchal Translucency Measurement in First-Trimester Ultrasound Screening in a Setting With First-Tier NIPT for Aneuploidy Screening
- PMID: 41353714
- DOI: 10.1002/pd.70047
Clinical Utility of Nuchal Translucency Measurement in First-Trimester Ultrasound Screening in a Setting With First-Tier NIPT for Aneuploidy Screening
Abstract
Objective: To investigate the additional clinical value of nuchal translucency (NT) measurement at the first-trimester anomaly scan (FTAS) in a setting with first-tier non-invasive prenatal testing (NIPT).
Method: This nationwide prospective cohort study, part of the IMITAS study on FTAS implementation, included all pregnancies with increased NT (≥ 3.5 mm) at FTAS, subsequently referred for detailed diagnostic scans at eight Dutch tertiary centers (Nov 2021-Nov 2022). Women with abnormal dating scans, abnormal NIPT before FTAS, or high-risk for fetal anomalies were not eligible for FTAS and received diagnostic ultrasound directly. The primary outcome was prenatal diagnosis of structural or genetic anomalies based on pre- and postnatal findings.
Results: FTAS was performed in 129,704 pregnancies, of which 230 (0.18%) had an increased NT. Anomalies were detected in 33.9% of these cases. Genetic anomalies included 76.8% aneuploidies, 14.3% SNVs, 8.9% CNVs; 39.3% beyond NIPT's detection scope. Trisomy 21/18 was diagnosed in 29.3% referred for increased NT without prior NIPT; 73.5% of these opted for termination. Anomaly prevalence increased with greater NT thickness.
Conclusion: NT measurement adds value in a national screening program including FTAS and NIPT. Prenatal counseling should address trisomies and other genetic abnormalities as a potential result of an abnormal FTAS, particularly when NIPT is declined.
Keywords: aneuploidy; chromosome disorders; congenital abnormalities; early diagnosis; fetal screening; noninvasive prenatal testing; nuchal translucency measurement; prenatal ultrasonography.
© 2025 The Author(s). Prenatal Diagnosis published by John Wiley & Sons Ltd.
References
-
- K. H. Nicolaides, G. Azar, D. Byrne, C. Mansur, and K. Marks, “Fetal Nuchal Translucency: Ultrasound Screening for Chromosomal Defects in First Trimester of Pregnancy,” BMJ 304, no. 6831 (April 1992): 867–869, https://doi.org/10.1136/bmj.304.6831.867.
-
- M. L. Brizot, R. J. Snijders, J. Butler, N. A. Bersinger, and K. H. Nicolaides, “Maternal Serum hCG and Fetal Nuchal Translucency Thickness for the Prediction of Fetal Trisomies in the First Trimester of Pregnancy,” British Journal of Obstetrics and Gynaecology 102, no. 2 (February 1995): 127–132, https://doi.org/10.1111/j.1471‐0528.1995.tb09065.x.
-
- K. R. M. van der Meij, E. A. Sistermans, M. V. E. Macville, et al., “TRIDENT‐2: National Implementation of Genome‐Wide Non‐Invasive Prenatal Testing as a First‐Tier Screening Test in the Netherlands,” American Journal of Human Genetics 105, no. 6 (December 2019): 1091–1101, https://doi.org/10.1016/j.ajhg.2019.10.005.
-
- Gezondheidsraad. “De Niet‐Invasieve Prenatale Test (NIPT) Als Bevolkingsonderzoek,” accessed February 13, 2025, https://www.gezondheidsraad.nl/documenten/adviezen/2023/02/20/advies‐wbo....
-
- Milieu. RvVe. “Combinatietest Stopt Vanaf 1 Oktober,” (2021), https://www.pns.nl/nieuws/combinatietest‐stopt‐vanaf‐1‐oktober‐2021#:~:t....
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
